Dunsire views learning new, complex domains like finance as layering peanut butter on bread. The first layer is thin and doesn't stick well, but each subsequent layer builds on the last. This iterative approach fosters the confidence that any subject can be mastered through persistence and curiosity.
During layoffs at Millennium, Dunsire ensured departing staff were treated with respect, even inviting them to the holiday party. She understood that the remaining employees—the company's lifeblood—are watching. Demonstrating compassion ensures they stay fully committed, rather than becoming protective and reserved.
When a lead drug failed at Forum Therapeutics, Dunsire meticulously framed it as "this molecule couldn't deliver," not "we failed." This critical distinction protects the confidence and reputation of a highly skilled team that executed flawlessly on a scientific hypothesis that ultimately proved incorrect.
Deborah Dunsire's transition from physician to pharma wasn't cemented by office work, but by seeing the real-world impact on patients at a transplant games event. This experience revealed she could positively affect more lives at scale, providing a powerful, motivating purpose that sustained her career.
When Millennium cut free milk to save $60,000, it triggered an employee outcry. The issue wasn't the milk but the signal it sent: the company must be failing. This undermined confidence. Reversing the decision and launching a playful "Got Milk?" campaign showed leadership listened and valued morale.
To ensure critical safety or compliance issues are never silenced by bureaucracy, Dunsire gave the heads of these functions a dotted-line reporting structure to her. Regular one-on-one meetings built a relationship, lowering the psychological barrier for them to raise urgent concerns directly.
In assessing the Millennium CEO role, Dunsire focused on Velcade's clinical data. Believing the drug was "remarkable," she reasoned that commercialization was a solvable problem. Her core thesis: a truly effective product will inevitably get used, making the turnaround a worthwhile risk.
The Takeda-Millennium acquisition was unique because Takeda wanted the people as a foundation for its new oncology unit. This focus on human capital allowed Dunsire to announce that all employees would keep their jobs—a rarity that preserved culture and enabled a smoother integration.
Integrating agile Millennium into 238-year-old Takeda revealed a core conflict. Millennium prioritized short-term speed, while Takeda valued long-term capability building. Understanding Takeda would sacrifice speed to train more people for the future was key to navigating disagreements and integrating successfully.
Dunsire was drawn to Millennium because its founding CEO, Mark Levin, had the humility to recognize the company needed a different leader for its commercial stage. This lack of ego is rare and signaled a healthy culture focused on the company's success over any individual's.